Says will continue to pursue opportunities to improve tax rate during the remainder of the year. Sees FY impact of amortization related to Synthes of approximately $550M on a pretax basis. Sees FY EPS growth rate between 4.5%-6.5% on constant currency basis. Says certain hospitals predicting lower levels of procedures volume than they had previously indicated.
Happy demi-anniversary, stock market rally. Will the honeymoon ever end?